

USSN 10/800,241

CT-2774 NP

Remarks

Status of the Claims. Claims 1-16 are pending. Claims 1-16 were rejected by the examiner.

Rejection based on 35 USC 112, first paragraph. Claims 1-16 were rejected for not enabling the claim term "solvate." This term has been deleted from all claims. Because the basis for this rejection has been removed, the applicants respectfully request the examiner withdraw this rejection.

Rejection based on 35 USC 112, second paragraph. Claims 15-16 were rejected for indefiniteness.

Claim 15 was rejected for not reciting "a pharmaceutically acceptable carrier" as stipulated by the examiner. The applicants amended the claim to read "A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier."

Claim 16 was rejected for depending on the composition of claim 15. The applicants amended the claim to read "A method of treating depression or anxiety comprising the administration of a compound of claim 1."

The applicants believe this removes the basis for the rejection of these claims and respectfully request the examiner to withdraw this rejection.

The applicants believe the application is now in allowable form and respectfully request favorable reconsideration. If any issues remain regarding the allowance of this application, the Examiner is respectfully invited to contact the applicants' agent, James Epperson, by phone (203-677-6974), fax (203-677-6900), or e-mail (james.epperson@bms.com).

Respectfully submitted,

Date: 4/20/2006
Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

James Epperson
James Epperson
Agent for Applicants
Reg. No. 52,867
Phone: (203) 677-6974